Liver Int:在人类和动物肝细胞癌模型中:改变的脂肪酸结合蛋白4(FABP4)的表达和功能

2017-11-26 MedSci MedSci原创

以上数据表明FABP4,正常情况下在肝脏中不表达的FABP,可以由肝细胞和HCC细胞合成和分泌。FABP4可能在调节肥胖相关肿瘤的进展中,发挥重要作用。

研究背景:肝细胞癌(HCC)是癌症相关死亡的第三个主要原因。HCC发生的危险因素有:病毒性肝炎、酒精和肥胖。脂肪酸结合蛋白(FABPs)结合长链游离脂肪酸(FFAs),以组织特异性的方式表达。在肝脏中主要以FABP1的形式存在,在脂肪细胞中主要以FABP4的形式存在。本研究旨在调查人类和动物肥胖相关的肝癌中FABPs1-9的表达与功能。

研究方法:在小鼠肥胖促进的肝癌中,研究FABP1-9的表达与功能。依据这些数据,在体外HepG2和HuH7细胞中,分析FABP4的表达与功能。检测不同肝脏病因患者血清FABP4水平。

研究结果:独立与肿瘤状态,肥胖小鼠肝脏中,FABP4 mRNA和蛋白表达增加,同时血清FABP4水平增加。在体外,通过脂肪酸治疗,HCC中可以检测到FABP4表达,并导致FABP4释放到培养基。使用外源性FABP4,可诱导人类HCC细胞增生和迁移显著性增强。患者血清表明,患有潜在肝病的患者,特别是非酒精性脂肪肝(NAFLD)和HCC的患者中,FABP4显著增加。

研究结论:以上数据表明FABP4,正常情况下在肝脏中不表达的FABP,可以由肝细胞和HCC细胞合成和分泌。FABP4可能在调节肥胖相关肿瘤的进展中,发挥重要作用。

原始出处


Thompson KJ, Austin RG, Nazari SS, et al. Altered fatty acid binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int, 2017, Nov 24. doi: 10.1111/liv.13639.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978612, encodeId=973719e861259, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 31 18:22:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049823, encodeId=fd0e2049823ba, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Oct 05 13:22:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863328, encodeId=c5ea18633289f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 17 23:22:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978612, encodeId=973719e861259, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 31 18:22:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049823, encodeId=fd0e2049823ba, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Oct 05 13:22:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863328, encodeId=c5ea18633289f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 17 23:22:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-10-05 wleon8895
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978612, encodeId=973719e861259, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 31 18:22:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049823, encodeId=fd0e2049823ba, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Oct 05 13:22:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863328, encodeId=c5ea18633289f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 17 23:22:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-01-17 xjy02